Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VA694 is a small molecule and a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the vicinal diaryl-substituted heterocyclic class. It has been investigated for its potential antitumor activity, specifically its ability to inhibit the growth of colorectal carcinoma (HT-29) and breast carcinoma (MDA-MB-231) cells. While it demonstrates growth-inhibitory effects, it has been shown to be less potent than related compounds like VA1213 in preclinical in vitro assays. Its mechanism involves the inhibition of COX-2, an enzyme frequently overexpressed in various cancers and associated with tumor progression and signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VA694.